#United States #New York #financing #Klotho Neurosciences #KLTO

Klotho Neurosciences Raises Over $11 Million

Company Update
On June 16, 2025, Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biogenetics firm located in the U.S., disclosed pivotal financial milestones that point towards a promising future. Over the past ten days, the company has successfully raised over $11 million in funding, primarily through the exercise of existing warrants by investors. As a result, Klotho believes that it meets and exceeds the stockholders' equity requirements set forth by Nasdaq, ensuring its continued listing.

Debt-Free Transformation
In addition, Klotho has utilized approximately $3.1 million from the raised capital to completely eliminate all outstanding debt, thereby achieving a debt-free status. This financial health allows the company to focus on its core mission without the burden of liabilities.

About Klotho Neurosciences
Klotho Neurosciences specializes in developing innovative cell and gene therapies, leveraging a patented form of the anti-aging Klotho gene (s-KL). Its focus is on addressing neurodegenerative and age-related diseases, including prominent disorders such as ALS, Alzheimer's, and Parkinson's disease. The company is committed to transforming treatment approaches using their unique proprietary technologies for cell and gene therapy.

Expert Management
Klotho is backed by a skilled team with extensive experience in biopharmaceutical product development and commercialization. This expertise underpins the company’s ambition to introduce groundbreaking therapeutic solutions that can significantly improve patients' quality of life.

Looking Forward
The company acknowledges the importance of its recent achievements, not only from a financial perspective but also in terms of reaching important compliance metrics. However, the road ahead is laden with challenges, including navigating the complex biopharmaceutical landscape and consistently meeting product development goals.

Klotho's promising funding structure and revitalized financial status are expected to provide the leverage needed to propel the company toward its ambitious objectives. The collective efforts of the management team, investors, and stakeholders position Klotho on a trajectory that holds hope for innovation in treating challenging medical conditions.

Conclusion
In summary, Klotho Neurosciences is emerging as a strong player in the biogenetics field with new capital to enhance its operations and eliminate past hurdles. The recent funding, combined with the removal of all debt, paves the way for future growth, development, and ultimately, patient impact. Stakeholders and market observers alike will be keen to monitor Klotho's progress, as the company makes strides toward fulfilling its vision of advancing health solutions for neurodegenerative diseases.